Mylan has announced that the US Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on all claims against 2 patents that cover Sanofi’s innovator insulin glargine injection, Lantus.
Mylan has announced that the US Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings on all claims against 2 patents that cover Sanofi’s innovator insulin glargine injection, Lantus. The patents being challenged, US Patents number 7,476,652 and number 7,713,930, relate to formulation. Mylan filed the petitions for IPR of these patents in June 2017.
Mylan’s New Drug Application (NDA) for a follow-on insulin glargine product, in both vial and pen dosage presentations, is currently under review by the FDA. (In the United States, insulins are currently regulated as drugs and not as biologics; hence, drug makers must submit NDAs, rather than biologics license applications, for follow-on versions of originator insulin products.) Announcement of the IPR proceedings follows an October 2017 lawsuit, filed against Mylan by Sanofi, alleging that Mylan has infringed on 18 of the patents that cover Lantus. The October suit was triggered by Mylan’s submission of its NDA.
Heather Bresch, CEO of Mylan, said in a statement, "The PTAB's decision to institute IPR proceedings against the [2] Orange Book-listed patents for Lantus is another step forward in our ongoing efforts to bring an interchangeable insulin glargine to diabetes patients as soon as possible.” She added, “There are more than 29 million people in the [United States] living with diabetes who deserve access to more affordable treatment options. As a leading producer of oral diabetes medicines, we are deeply committed to this patient community and believe bringing lower-cost alternatives…will fulfill a critical medical need."
The instituted petition for IPR proceedings could help clear the way for Mylan to launch its yet-to-be-approved insulin product as a challenger to the high-earning Lantus. Mylan estimates that total sales for Lantus and Lantus SoloSTAR (a pen presentation of Lantus) for the 12 months ending on October 31, 2017, were approximately $2.74 billion and $4.98 billion, respectively.
Already competing for the US insulin glargine market is Boehringer Ingelheim’s (BI) Basaglar, the first FDA-approved insulin glargine follow-on product. Basaglar launched in the United States in 2016 after BI concluded a lengthy litigation with Sanofi over its Lantus patents. Since its launch, competition from Basaglar has produced declines in Sanofi’s share of the insulin market; in the second quarter of 2017; Sanofi’s US sales of Lantus and Toujeo (another Sanofi insulin glargine product) slipped by 23.9%. Sanofi attributed its reduced sales to the exclusion of Lantus from commercial formularies, such as those of CVS Health and UnitedHealthcare. In addition, European sales of insulin glargine sank by 2% after to competition from approved European biosimilar insulins.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.